NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00480-4184-89 | 00480-4184 | Pazopanib | Pazopanib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms | Oral | Oct 20, 2023 | In Use | |
00480-4320-01 | 00480-4320 | Plerixafor | Plerixafor | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Jul 28, 2023 | In Use | |
00480-4514-01 | 00480-4514 | Pemetrexed | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 31, 2022 | In Use | |
00480-4515-01 | 00480-4515 | Pemetrexed | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 31, 2022 | In Use | |
00480-4516-01 | 00480-4516 | Pemetrexed | Pemetrexed | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Jun 1, 2022 | In Use | |
00480-5425-89 | 00480-5425 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | Jan 3, 2023 | In Use | |
00480-9259-08 | 00480-9259 | Octreotide Acetate | Octreotide Acetate | 3.33 mg/ml | Hormonal Therapy | Somatostatin Analog | Intramuscular | Oct 1, 2024 | In Use | ||
00480-9262-08 | 00480-9262 | Octreotide Acetate | Octreotide Acetate | 3.33 mg/ml | Hormonal Therapy | Somatostatin Analog | Intramuscular | Oct 1, 2024 | In Use | ||
00480-9772-01 | 00480-9772 | Fludarabine Phosphate | Fludarabine Phosphate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug 31, 2023 | In Use | |
00517-0420-01 | 00517-0420 | ESTRADIOL VALERATE | ESTRADIOL VALERATE | 20.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | Mar 1, 2020 | In Use | ||
00517-0440-01 | 00517-0440 | ESTRADIOL VALERATE | ESTRADIOL VALERATE | 40.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | Mar 1, 2020 | In Use | ||
00517-0745-01 | 00517-0745 | Pamidronate Disodium | Pamidronate Disodium | 3.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Jul 16, 2010 | Aug 24, 2012 | No Longer Used | |
00517-0746-01 | 00517-0746 | Pamidronate Disodium | Pamidronate Disodium | 9.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Aug 9, 2010 | Nov 1, 2012 | No Longer Used | |
00517-0920-08 | 00517-0920 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Apr 1, 2017 | In Use | |
00517-4300-01 | 00517-4300 | Paclitaxel | PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 2, 2023 | In Use | |
00517-4901-25 | 00517-4901 | Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 4.0 mg/mL, 4.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-Articular, Intra-articular, Intralesional, IM, IV, Intralesional, Intramuscular, Intravenous, Soft Tissue | Sep 30, 1990 | Nov 8, 2016 | No Longer Used |
00517-4905-25 | 00517-4905 | Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 4.0 mg/mL, 4.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-Articular, Intra-articular, Intralesional, IM, IV, Intralesional, Intramuscular, Intravenous, Soft Tissue | Sep 30, 1990 | Nov 8, 2016 | No Longer Used |
00517-4930-25 | 00517-4930 | Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 4.0 mg/mL, 4.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-Articular, Intra-articular, Intralesional, IM, IV, Intralesional, Intramuscular, Intravenous, Soft Tissue | Sep 30, 1990 | Nov 8, 2016 | No Longer Used |
00527-1242-02 | 00527-1242 | Fludarabine Phosphate | Fludarabine Phosphate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Dec 31, 2019 | In Use | |
00527-1450-06 | 00527-1450 | Dronabinol | Dronabinol | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | May 18, 2018 | In Use | |
00527-1451-06 | 00527-1451 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | May 18, 2018 | In Use | |
00527-1452-06 | 00527-1452 | Dronabinol | Dronabinol | 10.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | May 18, 2018 | In Use | |
00527-1712-30 | 00527-1712 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Oct 29, 2014 | Jun 16, 2017 | No Longer Used | |
00527-1726-40 | 00527-1726 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Jul 1, 2010 | In Use | |
00527-1726-41 | 00527-1726 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Jul 1, 2010 | In Use |
Found 11120 results — Export these results